Trials no longer actively enrolling patients:
- Bespoke IO 20-043-NCP (Natera) – A BESPOKE Study of ctDNA Guided Immunotherapy for Non-Small cell lung cancer, Melanoma, and Colorectal cancer. (NCT Number: NCT04761783)
- Bespoke 20-041-NCP (Natera) – An Observational Study of ctDNA Guided Therapy in Colorectal Cancer. (NCT Number: NCT04264702)
- CORFU (AstraZeneca) – Retrospective/Observational Study of Risk of Adverse Events in NSCLC Patients Treated with Immune Checkpoint Inhibitors Followed by EGFR Tyrosine Kinase Inhibitors
- EQ132-201 (EQRx) – A Phase 2 Study to Evaluate the Safety and Efficacy of Lerociclib in Participants with Advanced Breast Cancer (Sponsor: EQRx, Inc; NCT Number: NCT05085002)
- I3Y-MC-JPCW(b) (Eli Lilly) – A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib plus Standard Adjuvant Endocrine Therapy in Participants with High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy (NCT number: NCT04752332)
- KRYSTAL 12 (Mirati) – Phase 3 Study of MRTX849 vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-12) (NCT Number: NCT04685135)
- LOXO-BTK-20019 (Loxo Oncology, Inc) – Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321) (NCT Number: NCT04662255)
- PARADIGM (VastBiome) – Pursuit to Analyze and Reveal Associated Drivers of Immunotherapy outcomes through the Gut Microbiome (NCT Number: NCT05037825)
- Prevalence (Janssen Research & Development) – Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer. Observational study (NCT number: NCT03871816)